Treatment-Resistant Schizophrenia
Conditions
Interventions
MST group:Combining drug therapy with magnetic seizure therapy.
Drug Treatment group:Antipsychotic Drugs
Sponsors
Nanjing Brain Hospital
Eligibility
Sex/Gender
All
Age
16 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1.Diagnosis of schizophrenia according to DSM-5 diagnostic criteria; 2.According to the Treatment Response and Resistance in Psychosis ( TRRIP ): assessment using standardized scales such as PANSS; the severity of the symptoms was at least moderately severe; duration >= 12 weeks; an effective scale was used to assess functional impairment above moderate. Treatment dose >= 600 mg / d chlorpromazine equivalent, treatment time under treatment dose >= 6 weeks, sufficient and sufficient course of treatment with >= 2 different antipsychotics; 3.Age over 16 years old, under 50 years old, gender unlimited; 4.Right-handed; 5.Be able to sign a written informed consent;
Exclusion criteria
Exclusion criteria: 1.Patients with other mental disorders after evaluation by psychiatrists; 2.Patients with severe physical diseases such as brain organic diseases, cardiovascular diseases, tumors and so on; 3.Abnormal laboratory tests affect the efficacy of the study or affect the safety of the subjects; 4.Intracranial metal foreign matters, patients with cardiac pacemakers, cochlear implants, etc; 5.Pregnant, lactating women or those planning to become pregnant during the trial; 6.Patients who had received ECT treatment within 3-6 months, or who had previously received ECT treatment were ineffective; 7.Other situations that the researchers believe are not suitable for participating in the clinical trial;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MATRIC Consensus Cognitive Battery, MCCB;Autobiographical Memory Test, AMT;Positive and Negative Syndrome Scale score, PANSS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment Emergent Symptom Scale, TESS;estradiol;luteinizing hormone;progesterone;prolactin;testosterone;follicle stimulating hormone;Changes of brain structure and functional imaging;Richmond Agitation-Sedation Scale, RASS;The Confusion Assessment Method, CAM-ICU;IL-1ß, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17, IFN-?, TNF-a, IFN-a;S-100 protein;blood cells analysis; | — |
Countries
China
Contacts
Public ContactYuxiu Sui
Nanjing Brain Hospital
Outcome results
None listed